688266 泽璟制药
已收盘 05-13 15:00:00
资讯
新帖
简况
泽璟制药盐酸吉卡昔替尼片新药申请获受理
财中社 · 08:33
泽璟制药盐酸吉卡昔替尼片新药申请获受理
泽璟制药：盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获得受理
格隆汇 · 08:21
泽璟制药：盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获得受理
泽璟制药：盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获受理
美港电讯 · 08:20
泽璟制药：盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获受理
泽璟制药-U涨5% 纳入科创生物医药指数
智选洞察 · 01:35
泽璟制药-U涨5% 纳入科创生物医药指数
泽璟制药-U大跌5% 券商看好
智选洞察 · 05-12 01:30
泽璟制药-U大跌5% 券商看好
科创医药指数ETF飘红，泽璟制药-U涨超3%，机构：看好创新药产业链在今年持续良好表现
21世纪经济报道 · 05-09
科创医药指数ETF飘红，泽璟制药-U涨超3%，机构：看好创新药产业链在今年持续良好表现
三年暴涨400%，这家未盈利药企凭什么？
CPHI制药在线 · 05-08
三年暴涨400%，这家未盈利药企凭什么？
泽璟制药-U05月07日主力净流出6626.1万元 散户资金买入
市场透视 · 05-07
泽璟制药-U05月07日主力净流出6626.1万元 散户资金买入
泽璟制药-U大跌5% 券商看好
智选洞察 · 05-06
泽璟制药-U大跌5% 券商看好
逆势大涨400%！国产Biotech又一黑马杀出
谈思生物 · 05-02
逆势大涨400%！国产Biotech又一黑马杀出
华源证券：给予泽璟制药买入评级
证券之星 · 04-30
华源证券：给予泽璟制药买入评级
A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨
美港电讯 · 04-30
A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨
【机构调研记录】富荣基金调研丰立智能、泽璟制药等6只个股（附名单）
证券之星 · 04-29
【机构调研记录】富荣基金调研丰立智能、泽璟制药等6只个股（附名单）
【机构调研记录】华西基金调研联创电子、泽璟制药等3只个股（附名单）
证券之星 · 04-29
【机构调研记录】华西基金调研联创电子、泽璟制药等3只个股（附名单）
【私募调研记录】理成资产调研上海家化、泽璟制药等3只个股（附名单）
证券之星 · 04-29
【私募调研记录】理成资产调研上海家化、泽璟制药等3只个股（附名单）
【私募调研记录】中欧瑞博调研上海家化、泽璟制药
证券之星 · 04-29
【私募调研记录】中欧瑞博调研上海家化、泽璟制药
泽璟制药-U04月28日主力净流入128.0万元 散户资金抛售
市场透视 · 04-28
泽璟制药-U04月28日主力净流入128.0万元 散户资金抛售
泽璟制药：4月21日召开业绩说明会，天风证券、华源证券等多家机构参与
证券之星 · 04-28
泽璟制药：4月21日召开业绩说明会，天风证券、华源证券等多家机构参与
海归盛泽林深耕创新药收获50亿财富 泽璟制药累亏28亿研发费连降亟待谋变
长江商报 · 04-28
海归盛泽林深耕创新药收获50亿财富 泽璟制药累亏28亿研发费连降亟待谋变
泽璟制药：公司商业贿赂被罚年报未如实披露，研发投入下滑、销售费率超50%
九号观察 · 04-26
泽璟制药：公司商业贿赂被罚年报未如实披露，研发投入下滑、销售费率超50%
加载更多
公司概况
公司名称：
苏州泽璟生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-23
主营业务：
苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是药品。
发行价格：
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药","latestPrice":93.2,"timestamp":1747119600000,"preClose":91.73,"halted":0,"volume":4637640,"delay":0,"changeRate":0.016,"floatShares":265000000,"shares":265000000,"eps":-0.4783,"marketStatus":"已收盘","change":1.47,"latestTime":"05-13 15:00:00","open":95.05,"high":97.78,"low":92.5,"amount":441000000,"amplitude":0.0576,"askPrice":93.24,"askSize":5,"bidPrice":93.2,"bidSize":325,"shortable":0,"etf":0,"ttmEps":-0.4783,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747186200000},"marketStatusCode":5,"adr":0,"adjPreClose":91.73,"symbolType":"stock_kcb","openAndCloseTimeList":[[1747099800000,1747107000000],[1747112400000,1747119600000]],"highLimit":100.9,"lowLimit":82.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":20.12,"roa":"--","roe":"--","epsLYR":-0.52,"committee":0.85,"marketValue":24671000000,"turnoverRate":0.0175,"status":0,"afterMarket":{"amount":0,"volume":0,"close":93.2,"buyVolume":0,"sellVolume":0,"time":1747121638029,"indexStatus":"已收盘 05-13 15:30:00","preClose":91.73},"floatMarketCap":24671000000},"requestUrl":"/m/hq/s/688266","defaultTab":"news","newsList":[{"id":"2535389712","title":"泽璟制药盐酸吉卡昔替尼片新药申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2535389712","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535389712?lang=zh_cn&edition=full","pubTime":"2025-05-13 16:33","pubTimestamp":1747125180,"startTime":"0","endTime":"0","summary":"5月13日，泽璟制药（688266）发布公告，公司于2025年5月12日收到国家药品监督管理局核准签发的《受理通知书》，其盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获得受理。盐酸吉卡昔替尼是一种新型的JAK抑制剂，具有显著抑制JAK激酶四个亚型的能力，能够有效抑制炎症并促进毛囊再生。目前在我国尚无国产JAK抑制剂类药物获批用于治疗重度斑秃。公司还在进行多个免疫炎症性疾病的临床研究，吉卡昔替尼片在治疗重度斑秃的III期临床试验及其他适应症的临床试验已取得成功。2025年一季度，泽璟制药实现收入1.68亿元，归母净利润-2826万元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-05-13/doc-inewmhrv0193869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2535715491","title":"泽璟制药：盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2535715491","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535715491?lang=zh_cn&edition=full","pubTime":"2025-05-13 16:21","pubTimestamp":1747124495,"startTime":"0","endTime":"0","summary":"格隆汇5月13日丨泽璟制药(688266.SH)公布，收到国家药品监督管理局核准签发的《受理通知书》，公司递交的盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请（NDA）获得受理，这是盐酸吉卡昔替尼片第二个申请新药上市的适应症。盐酸吉卡昔替尼（曾用名：盐酸杰克替尼）是一种新型的JAK抑制剂，对JAK激酶的四个亚型JAK1、JAK2、JAK3和TYK2都有显著的抑制作用。吉卡昔替尼能够有效抑制炎症和抑制T细胞过度激活，亦能显著增加真皮层的厚度和促进毛囊再生，增加毛囊密度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505131621369758167e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505131621369758167e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2535157317","title":"泽璟制药：盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2535157317","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535157317?lang=zh_cn&edition=full","pubTime":"2025-05-13 16:20","pubTimestamp":1747124455,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2535757999","title":"泽璟制药-U涨5% 纳入科创生物医药指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2535757999","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535757999?lang=zh_cn&edition=full","pubTime":"2025-05-13 09:35","pubTimestamp":1747100142,"startTime":"0","endTime":"0","summary":"05月13日，泽璟制药-U股价大幅上涨，截至09点35分，泽璟制药-U上涨5.00%，报96.32元/股，成交8927万元，换手率0.35%。中证指数有限公司将于2025年5月13日正式发布中证科创创业生物医药指数和中证科创创业新能源指数，为市场提供更丰富的投资标的。资金动向截止发稿，泽璟制药-U获得主力净流出218万元，其中超大单流入42万元，大单流出260万元。主营业务及业绩泽璟制药-U公司主营业务为化学新药及生物新药的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250513093814a47c0964&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250513093814a47c0964&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688266","000683.SH","BK0239","159938"],"gpt_icon":0},{"id":"2534126893","title":"泽璟制药-U大跌5% 券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2534126893","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534126893?lang=zh_cn&edition=full","pubTime":"2025-05-12 09:30","pubTimestamp":1747013447,"startTime":"0","endTime":"0","summary":"05月12日，泽璟制药-U股价大幅下跌，截至09点30分，泽璟制药-U下跌5.08%，报94.44元/股，创近1个月新低，成交2306万元，换手率0.09%，振幅2.86%。资金动向截止发稿，泽璟制药-U获得主力净流入68万元，其中超大单流入135万元，大单流出67万元。主营业务及业绩泽璟制药-U公司主营业务为化学新药及生物新药的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512093422a6db89ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512093422a6db89ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2534487112","title":"科创医药指数ETF飘红，泽璟制药-U涨超3%，机构：看好创新药产业链在今年持续良好表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2534487112","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534487112?lang=zh_cn&edition=full","pubTime":"2025-05-09 10:42","pubTimestamp":1746758531,"startTime":"0","endTime":"0","summary":"5月9日，三大指数集体低开后弱势震荡，上证科创板生物医药指数逆市走强。相关ETF方面，科创医药指数ETF截至发稿涨0.1%，换手率4.3%，成交额超1152万元。科创医药指数ETF紧密跟踪上证科创板生物医药指数，上证科创板生物医药指数从科创板市场中选取50只市值较大的生物医药、生物医学工程、生物农业、生物质能、其他生物业等领域上市公司证券作为指数样本，反映科创板市场代表性生物医药产业上市公司证券的整体表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505091051589753f4e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505091051589753f4e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688266","BK0239","159992","588700"],"gpt_icon":0},{"id":"2533906865","title":"三年暴涨400%，这家未盈利药企凭什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2533906865","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533906865?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:11","pubTimestamp":1746695471,"startTime":"0","endTime":"0","summary":"截至2025年4月21日收盘，泽璟制药市值为279.27亿元，从2022年资本寒冬以来，泽璟制药连续三年大涨，涨幅超400%。对于一家尚未盈利的药企来说，泽璟制药凭什么？2020年1月，泽璟制药成功在科创板上市，成为科创板首家未盈利公司。2024年，泽璟制药的重组人凝血酶已被纳入国家医保药品目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508175141a6d77848&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508175141a6d77848&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2533467060","title":"泽璟制药-U05月07日主力净流出6626.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2533467060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533467060?lang=zh_cn&edition=full","pubTime":"2025-05-07 15:20","pubTimestamp":1746602412,"startTime":"0","endTime":"0","summary":"05月07日, 泽璟制药-U股价跌4.72%，报收96.80元，成交金额4.4亿元，换手率1.68%，振幅7.02%，量比1.32。泽璟制药-U今日主力资金净流出6626.1万元，上一交易日主力净流入1933.3万元。该股近5个交易日下跌3.95%，主力资金累计净流出2901.0万元；近20日主力资金累计净流出1.8亿元，其中净流出天数为9日。净流出前三个股分别为兴齐眼药、泽璟制药-U、百济神州-U。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507164527a6d617ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507164527a6d617ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2533351052","title":"泽璟制药-U大跌5% 券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2533351052","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533351052?lang=zh_cn&edition=full","pubTime":"2025-05-06 10:31","pubTimestamp":1746498708,"startTime":"0","endTime":"0","summary":"05月06日，泽璟制药-U股价大幅下跌，截至10点31分，泽璟制药-U下跌5.19%，报102.50元/股，成交1.62亿元，换手率0.58%。资金动向截止发稿，泽璟制药-U获得主力净流入1285万元，其中超大单流入885万元，大单流入400万元。主营业务及业绩泽璟制药-U公司主营业务为化学新药及生物新药的研发、生产及销售。最新财报显示，今年一季报，泽璟制药-U实现营业收入1.68亿元，同比增长54.87%，净利润为-2,826.22万元，同比增长28.45%，基本每股收益为-0.11元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506103153a6d46c7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506103153a6d46c7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2532814773","title":"逆势大涨400%！国产Biotech又一黑马杀出","url":"https://stock-news.laohu8.com/highlight/detail?id=2532814773","media":"谈思生物","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532814773?lang=zh_cn&edition=full","pubTime":"2025-05-02 15:00","pubTimestamp":1746169219,"startTime":"0","endTime":"0","summary":"然而，泽璟制药的股价却逆势飙升超过400%，其市净率更是远高于行业平均水平。2025年4月19日，泽璟制药发布了2024年年度报告。尽管毛利率高达93.06%，但公司存在21.03亿元的货币资金与8.82亿元短期借款并存的“存贷双高”现象，这反映出Biotech企业典型的资金管理困境。重组人凝血酶是中国唯一采用重组基因技术的产品，全球范围内仅有美国Zymogenetics公司的“Recothrom”为同类产品，并且已在境外上市销售多年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502190015a46fe918&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502190015a46fe918&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2531059064","title":"华源证券：给予泽璟制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2531059064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531059064?lang=zh_cn&edition=full","pubTime":"2025-04-30 22:31","pubTimestamp":1746023492,"startTime":"0","endTime":"0","summary":"华源证券股份有限公司刘闯近期对泽璟制药进行研究并发布了研究报告《业绩符合预期，关注重磅管线积极进展》，给予泽璟制药买入评级。 泽璟制药 投资要点： 事件：泽璟制药发布2024年年度报告及2025年第一季度报告。鉴于公司主业稳健增长，创新药研发进展积极，有望授权出海，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有12家机构给出评级，买入评级11家，增持评级1家；过去90天内机构目标均价为108.59。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000047983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688266"],"gpt_icon":0},{"id":"2531735757","title":"A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735757","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531735757?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:13","pubTimestamp":1745990033,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0405327148.USD","BK0196","LU0588546209.SGD","BK0209","LU2488822045.USD","BK0188","600276","BK1583","06978","06160","09969","LU2328871848.SGD","LU1064130708.USD","000963","688428","LU1969619763.USD","159982","BK0187","BK1500","LU1064131003.USD","BK0028","BK1574","688266","BK0239","688382","LU0405327494.USD","BK0060","BK0183","BK0132","399300","BK0012","002422","LU0307460666.USD","LU2148510915.USD","ONC","BK1161","LU1328615791.USD","BK4139","159992","BK1588","BK0175","688235"],"gpt_icon":0},{"id":"2531917562","title":"【机构调研记录】富荣基金调研丰立智能、泽璟制药等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2531917562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531917562?lang=zh_cn&edition=full","pubTime":"2025-04-29 08:05","pubTimestamp":1745885136,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月28日披露的机构调研信息，富荣基金近期对6家上市公司进行了调研，相关名单如下：1）丰立智能 调研纪要：丰立智能成立于1995年，从突破小模数螺旋锥齿轮加工难题起步，逐步扩展产品线至圆柱齿轮、粉末齿轮、精密机械件等，并在2022年上市募集资金投向机器人和新能源汽车领域。减速机及其配件业务毛利率下降，因市场竞争加剧和产品结构调整。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900009246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","301368","BK0259","BK0239"],"gpt_icon":0},{"id":"2531729122","title":"【机构调研记录】华西基金调研联创电子、泽璟制药等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2531729122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531729122?lang=zh_cn&edition=full","pubTime":"2025-04-29 08:04","pubTimestamp":1745885078,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月28日披露的机构调研信息，华西基金近期对3家上市公司进行了调研，相关名单如下：1）联创电子 调研纪要：联创电子在2025年的经营目标为实现营业收入110亿元，其中光学产业销售收入达到55亿元，并实现扭亏为盈。基因治疗产品显示良好安全性和疗效，双载荷DC分子具有协同作用。旗下最近一年表现最佳的公募基金产品为华西优选成长一年持有混合，最新单位净值为1.01，近一年增长26.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900009205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0214","BK0198","BK0108","BK0239","BK0076","002036"],"gpt_icon":0},{"id":"2531291485","title":"【私募调研记录】理成资产调研上海家化、泽璟制药等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2531291485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531291485?lang=zh_cn&edition=full","pubTime":"2025-04-29 08:02","pubTimestamp":1745884944,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月28日披露的机构调研信息，知名私募理成资产近期对3家上市公司进行了调研，相关名单如下：1）上海家化 调研纪要：上海家化对618有信心，核心品牌有望实现高双位数GMV增长。2）泽璟制药 调研纪要：泽璟制药介绍了其在研药物ZG006、ZG005、ZGGS18等的最新进展，以及未来3-5年的研发、商业化和国际化规划。理成长期业绩排名居前，曾获得三届四座私募金牛奖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025042900009049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","600315","BK0012","BK0196","BK0229","BK0188","BK0239","BK0070","BK0028"],"gpt_icon":0},{"id":"2531129114","title":"【私募调研记录】中欧瑞博调研上海家化、泽璟制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2531129114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531129114?lang=zh_cn&edition=full","pubTime":"2025-04-29 08:02","pubTimestamp":1745884944,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月28日披露的机构调研信息，知名私募中欧瑞博近期对2家上市公司进行了调研，相关名单如下：1）上海家化 调研纪要：上海家化对618有信心，核心品牌有望实现高双位数GMV增长。2）泽璟制药 调研纪要：泽璟制药介绍了其在研药物ZG006、ZG005、ZGGS18等的最新进展，以及未来3-5年的研发、商业化和国际化规划。取名\"兔子基金\"体现了中欧瑞博敬畏风险的投资文化，并始终把风险防范和管理摆在突出位置。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025042900009051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","BK0229","688266","600315","BK0012","BK0196","BK0070"],"gpt_icon":0},{"id":"2530405698","title":"泽璟制药-U04月28日主力净流入128.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2530405698","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530405698?lang=zh_cn&edition=full","pubTime":"2025-04-28 19:26","pubTimestamp":1745839588,"startTime":"0","endTime":"0","summary":"04月28日, 泽璟制药-U股价涨0.43%，报收101.21元，成交金额3.1亿元，换手率1.20%，振幅6.32%，量比0.70。泽璟制药-U今日主力资金净流入128.0万元，上一交易日主力净流出17.0万元。该股近5个交易日下跌4.07%，主力资金累计净流出1982.0万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1.8亿元，其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428194924a46a656f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428194924a46a656f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2530478251","title":"泽璟制药：4月21日召开业绩说明会，天风证券、华源证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2530478251","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530478251?lang=zh_cn&edition=full","pubTime":"2025-04-28 18:08","pubTimestamp":1745834896,"startTime":"0","endTime":"0","summary":"对于ZG006，公司制定了清晰的开发策略，正在积极推进ZG006治疗小细胞肺癌、神经内分泌癌的I/II期、II期临床研究。目前已经完成末线小细胞肺癌II期临床试验的入组，正在随访阶段。答：注射用ZG005是是全球率先进入临床研究的同靶点药物之一，目前全球范围内尚未有同类机制药物获批上市。公司已获得ZG005多项联合用药临床试验批文。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800028512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601162","BK0276","BK0239","161027","688266"],"gpt_icon":0},{"id":"2530498963","title":"海归盛泽林深耕创新药收获50亿财富 泽璟制药累亏28亿研发费连降亟待谋变","url":"https://stock-news.laohu8.com/highlight/detail?id=2530498963","media":"长江商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530498963?lang=zh_cn&edition=full","pubTime":"2025-04-28 08:18","pubTimestamp":1745799524,"startTime":"0","endTime":"0","summary":"近一年，泽璟制药股价翻倍上涨，盛泽林的持股财富也超过50亿元。2016年至2024年，公司累计亏损约28亿元。累亏28亿靠资本输血上市已有5年，泽璟制药尚未走出亏损的困境。根据最新年报披露，2024年，泽璟制药持续推进多纳非尼片进入医院和药房。2020年初，泽璟制药IPO上市成功，募资20.26亿元，2023年，公司通过定增募资12亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504280832179747bdfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504280832179747bdfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266","159992"],"gpt_icon":0},{"id":"2530798147","title":"泽璟制药：公司商业贿赂被罚年报未如实披露，研发投入下滑、销售费率超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530798147","media":"九号观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530798147?lang=zh_cn&edition=full","pubTime":"2025-04-26 17:25","pubTimestamp":1745659500,"startTime":"0","endTime":"0","summary":"不过值得注意的是，该项针对上市公司本身的行政处罚并未在年报中如实披露。1业绩连年亏损5年亏超16亿，研发投入逐年下滑泽璟制药虽说2020年在科创板上市了，但是其业绩表现可以说一言难尽。据泽璟制药年报披露，2024年销售费用高达2.71亿元，较2023年的2.5亿元增加了8.37%。如果从销售费用占同期营收的比例来看，泽璟制药的销售费用率超过了50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042617464694e399ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042617464694e399ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688266"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1747132052086,"stockEarnings":[{"period":"1week","weight":-0.1515},{"period":"1month","weight":-0.1319},{"period":"3month","weight":0.4138},{"period":"6month","weight":0.3372},{"period":"1year","weight":0.6588},{"period":"ytd","weight":0.4722}],"compareEarnings":[{"period":"1week","weight":0.0275},{"period":"1month","weight":0.0405},{"period":"3month","weight":0.0154},{"period":"6month","weight":-0.0204},{"period":"1year","weight":0.0681},{"period":"ytd","weight":0.0052}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7533人(较上一季度减少9.75%)","perCapita":"35139股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是药品。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药,688266,泽璟制药股票,泽璟制药股票老虎,泽璟制药股票老虎国际,泽璟制药行情,泽璟制药股票行情,泽璟制药股价,泽璟制药股市,泽璟制药股票价格,泽璟制药股票交易,泽璟制药股票购买,泽璟制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}